Sage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Estimates By $0.17 EPS

Sage Therapeutics (NASDAQ:SAGE) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17), Briefing.com reports. The company had revenue of $7.90 million for the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative return on equity of 54.17% and a negative net margin of 552.52%. The firm’s revenue for the quarter was up 139.4% on a year-over-year basis. During the same period in the prior year, the business earned ($2.46) earnings per share.

Sage Therapeutics Price Performance

Sage Therapeutics stock opened at $13.69 on Friday. Sage Therapeutics has a 52 week low of $10.92 and a 52 week high of $59.99. The company’s 50 day moving average price is $18.56 and its two-hundred day moving average price is $20.64.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wedbush reaffirmed a “neutral” rating and set a $24.00 target price on shares of Sage Therapeutics in a research report on Wednesday, April 17th. The Goldman Sachs Group decreased their price target on Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating for the company in a report on Friday. Morgan Stanley increased their price target on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. TD Cowen decreased their price target on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, April 18th. Finally, Canaccord Genuity Group decreased their price target on Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating for the company in a report on Friday. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $37.72.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.